SG11201803145RA - Methods and compositions for inducing hematopoietic cell differentiation - Google Patents
Methods and compositions for inducing hematopoietic cell differentiationInfo
- Publication number
- SG11201803145RA SG11201803145RA SG11201803145RA SG11201803145RA SG11201803145RA SG 11201803145R A SG11201803145R A SG 11201803145RA SG 11201803145R A SG11201803145R A SG 11201803145RA SG 11201803145R A SG11201803145R A SG 11201803145RA SG 11201803145R A SG11201803145R A SG 11201803145RA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- cell differentiation
- hematopoietic cell
- inducing hematopoietic
- Prior art date
Links
- 230000024245 cell differentiation Effects 0.000 title 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2311—Interleukin-11 (IL-11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562251016P | 2015-11-04 | 2015-11-04 | |
PCT/US2016/014918 WO2016123100A1 (en) | 2015-01-26 | 2016-01-26 | Methods and compositions for inducing hematopoietic cell differentiation |
US201662337093P | 2016-05-16 | 2016-05-16 | |
PCT/US2016/044122 WO2017078807A1 (en) | 2015-11-04 | 2016-07-26 | Methods and compositions for inducing hematopoietic cell differentiation |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201803145RA true SG11201803145RA (en) | 2018-05-30 |
Family
ID=58662624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201803145RA SG11201803145RA (en) | 2015-11-04 | 2016-07-26 | Methods and compositions for inducing hematopoietic cell differentiation |
Country Status (9)
Country | Link |
---|---|
US (5) | US10858628B2 (ja) |
EP (1) | EP3371301A4 (ja) |
JP (3) | JP2018533363A (ja) |
KR (1) | KR20180066263A (ja) |
CN (2) | CN115927199A (ja) |
AU (2) | AU2016348342B2 (ja) |
CA (1) | CA3003152A1 (ja) |
SG (1) | SG11201803145RA (ja) |
WO (1) | WO2017078807A1 (ja) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10626372B1 (en) | 2015-01-26 | 2020-04-21 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
EA201792414A1 (ru) | 2015-05-04 | 2018-06-29 | Сайтомкс Терапьютикс, Инк. | Антитела против cd166, активируемые антитела против cd166 и способы их применения |
JP2018520688A (ja) | 2015-07-21 | 2018-08-02 | ザ チルドレンズ メディカル センター コーポレーション | Pd−l1発現造血幹細胞およびその使用 |
CN108368520B (zh) | 2015-11-04 | 2023-01-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
CA3003152A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
WO2017127755A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
WO2017136479A1 (en) | 2016-02-01 | 2017-08-10 | Cedars-Sinai Medical Center | Systems and methods for growth of intestinal cells in microfluidic devices |
EP4180519A1 (en) * | 2016-04-15 | 2023-05-17 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
CA3035660A1 (en) | 2016-09-06 | 2018-03-15 | The Children's Medical Center Corporation | Immune cells derived from induced pluripotent stem cell |
US11932870B2 (en) | 2016-12-05 | 2024-03-19 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
WO2018140647A1 (en) | 2017-01-25 | 2018-08-02 | Cedars-Sinai Medical Center | In vitro induction of mammary-like differentiation from human pluripotent stem cells |
US20190359940A1 (en) * | 2017-02-07 | 2019-11-28 | Agency For Science, Technology And Research | Methods and kits for generating mimetic innate immune cells from pluripotent stem cells |
CA3052473A1 (en) | 2017-02-09 | 2018-08-16 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and compositions and methods thereof |
US11767513B2 (en) | 2017-03-14 | 2023-09-26 | Cedars-Sinai Medical Center | Neuromuscular junction |
TW201834669A (zh) | 2017-03-15 | 2018-10-01 | 美商歐卡生物系統公司 | 用於造血幹細胞移植的組合物及方法 |
WO2018176001A2 (en) | 2017-03-24 | 2018-09-27 | Cedars-Sinai Medical Center | Methods and compositions for production of fallopian tube epithelium |
AU2018257307A1 (en) * | 2017-04-26 | 2019-11-21 | Kyoto University | Hematopoietic progenitor cell marker |
CA3069804A1 (en) | 2017-07-14 | 2019-01-17 | Cytomx Therapeutics, Inc. | Anti-cd166 antibodies and uses thereof |
JP2020530997A (ja) * | 2017-08-08 | 2020-11-05 | サンガモ セラピューティクス, インコーポレイテッド | キメラ抗原受容体媒介性細胞標的化 |
KR102167548B1 (ko) * | 2017-09-21 | 2020-10-19 | 한국생명공학연구원 | 자연살해세포의 제조방법 및 그의 용도 |
US11879137B2 (en) | 2017-09-22 | 2024-01-23 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
CA3077344A1 (en) * | 2017-09-29 | 2019-04-04 | Regents Of The University Of Minnesota | Methods of making, expanding, and using a human progenitor t cell |
SG11202005173SA (en) | 2017-12-22 | 2020-06-29 | Fate Therapeutics Inc | Enhanced immune effector cells and use thereof |
SG11202006731VA (en) * | 2018-01-18 | 2020-08-28 | Agency Science Tech & Res | Method for differentiation of human pluripotent stem cell lines in suspension culture |
JP2021523700A (ja) * | 2018-04-30 | 2021-09-09 | シーダーズ−サイナイ メディカル センター | 早期発症型孤発性パーキンソン病の分子シグネチャの診断及び薬物スクリーニング |
EP3831936A4 (en) * | 2018-07-31 | 2022-04-13 | Thyas Co. Ltd. | METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS |
US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
US20220143084A1 (en) | 2019-02-15 | 2022-05-12 | Editas Medicine, Inc. | Modified natural killer (nk) cells for immunotherapy |
CN113767167A (zh) * | 2019-04-26 | 2021-12-07 | 科罗拉多大学董事会,法人 | 从诱导多能干细胞体内产生功能性和患者特异性胸腺组织 |
CA3139836A1 (en) * | 2019-05-09 | 2020-11-12 | Figene, Llc | Fibroblast generated patient-specific vaccines |
CN110106144B (zh) * | 2019-05-17 | 2021-10-08 | 苏州大学 | 一种诱导造血干细胞向前t系细胞分化的方法和试剂盒 |
WO2021024170A1 (en) * | 2019-08-05 | 2021-02-11 | Voloshin Sela Tali | Increasing cancer cells' sensitivity to tumor treating fields (ttfields) by inhibiting il11 activity |
US20220275335A1 (en) * | 2019-08-20 | 2022-09-01 | Adaptimmune Limited | Culture medium for haematopoietic induction |
GB201911957D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | Methods of producing haemogenic progenitor cells from pluripotent stem cells |
GB201911953D0 (en) * | 2019-08-20 | 2019-10-02 | Adaptimmune Ltd | T cell production fram RAG inacivated iPSCs |
JP2022550899A (ja) * | 2019-10-07 | 2022-12-05 | フェイト セラピューティクス,インコーポレイテッド | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
JP2022552314A (ja) * | 2019-10-17 | 2022-12-15 | フェイト セラピューティクス,インコーポレイテッド | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
CN114746543A (zh) * | 2019-11-13 | 2022-07-12 | 延世大学校产学协力团 | 分离纯培养血管内皮细胞的方法、维持血管内皮细胞特性的培养基和包括其的培养方法 |
JP2023501520A (ja) * | 2019-11-14 | 2023-01-18 | アムジエン・インコーポレーテツド | 造血前駆細胞の産生 |
MX2022010521A (es) * | 2020-02-28 | 2022-09-19 | Takeda Pharmaceuticals Co | Metodo para producir linfocitos citoliticos naturales a partir de celulas madre pluripotentes. |
CN115135754A (zh) * | 2020-02-28 | 2022-09-30 | 普渡研究基金会 | 在限定条件下从人多能干细胞生成主动脉-性腺-中肾样造血细胞 |
WO2021207251A1 (en) * | 2020-04-06 | 2021-10-14 | The Board Of Trustees Of The Leland Stanford Junior University | Generating populations of human blood and blood vessel progenitors from pluripotent stem cells |
EP4138893A1 (en) * | 2020-04-21 | 2023-03-01 | Intima Bioscience, Inc. | Cellular vaccine platform and methods of use |
CN111808812B (zh) * | 2020-08-31 | 2020-12-15 | 首都医科大学附属北京友谊医院 | 一种用于多能干细胞向造血干细胞分化的材料和方法 |
WO2022063226A1 (zh) * | 2020-09-24 | 2022-03-31 | 广州辑因医疗科技有限公司 | 化合物用于提高人造血干细胞移植效率的用途 |
CN112119977B (zh) * | 2020-10-15 | 2021-10-19 | 中国人民解放军军事科学院军事医学研究院 | Cd317诱导的抑郁和记忆损伤的小鼠模型的构建方法及其应用 |
EP4232567A1 (en) | 2020-10-26 | 2023-08-30 | Shoreline Biosciences, Inc. | Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells |
CN114525257A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达Tim-3阻断物的多能干细胞或其衍生物及应用 |
US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
EP4271798A1 (en) * | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
KR20220113586A (ko) * | 2021-02-05 | 2022-08-16 | 의료법인 성광의료재단 | 다능성 줄기세포 유래 조혈 내피세포를 이용한 유전자 편집된 세포의 제조방법 |
WO2022169297A1 (ko) * | 2021-02-05 | 2022-08-11 | 의료법인 성광의료재단 | 다능성 줄기세포 유래 조혈 내피세포로부터 림프구계세포의 분화 방법 |
GB202102297D0 (en) * | 2021-02-18 | 2021-04-07 | Adaptimmune Ltd | Methods of Producing Haemogenic Endothelial Cells from Pluripotent Stem Cells |
CN112831461B (zh) * | 2021-02-26 | 2023-08-08 | 澳门大学 | 一种诱导干细胞分化成中胚层谱系或滋养细胞谱系的方法及药物 |
EP4326852A1 (en) * | 2021-04-22 | 2024-02-28 | Artec Biotech, Inc. | Method for producing hematopoietic cells from stem cells using vascular organoids |
CA3220136A1 (en) * | 2021-05-14 | 2022-11-17 | Appia Bio, Inc. | Production of engineered t cells from stem cells |
AU2022292988A1 (en) * | 2021-06-15 | 2024-01-04 | Takeda Pharmaceutical Company Limited | Method for producing natural killer cells from pluripotent stem cells |
WO2023019213A1 (en) * | 2021-08-13 | 2023-02-16 | Simcere Innovation, Inc. | Three-dimensional culturing of pluripotent stem cells to produce hematopoietic stem cells |
KR20240051185A (ko) * | 2021-08-19 | 2024-04-19 | 세다르스-신나이 메디칼 센터 | 노화-관련 및 신경변성 질환의 예방 및 치료에서 ipsc-유래 면역 세포 |
KR20230038628A (ko) * | 2021-09-10 | 2023-03-21 | 의료법인 성광의료재단 | 전분화능 줄기세포 유래 조혈모세포 제조방법 및 상기 제조된 조혈모세포를 이용한 인간화 마우스 모델 제작방법 |
CN113801846A (zh) * | 2021-09-22 | 2021-12-17 | 南京艾尔普再生医学科技有限公司 | 一种从人诱导多能干细胞分化为自然杀伤细胞的方法 |
WO2023138680A1 (zh) * | 2022-01-20 | 2023-07-27 | 科济生物医药(上海)有限公司 | 诱导细胞分化的方法 |
CN114350608A (zh) * | 2022-01-27 | 2022-04-15 | 昭泰英基生物医药(香港)有限公司 | 一种诱导t细胞重编程为类nk细胞的组合物及其应用 |
CN114702591B (zh) * | 2022-05-17 | 2022-09-23 | 诺赛联合(北京)生物医学科技有限公司 | 成体细胞衍生的类器官制备技术 |
KR20230173249A (ko) | 2022-06-16 | 2023-12-27 | 대한민국(질병관리청 국립보건연구원장) | Dusp6가 결핍된 줄기세포 및 이의 용도 |
CN114774365B (zh) * | 2022-06-16 | 2022-08-23 | 呈诺再生医学科技(北京)有限公司 | 一种诱导iPSC分化获得CD34+细胞和NK细胞的方法及其应用 |
WO2023246820A1 (zh) * | 2022-06-20 | 2023-12-28 | 上海优替济生生物医药有限公司 | 体外诱导干细胞样记忆细胞的化合物及其应用 |
WO2023247722A1 (en) * | 2022-06-22 | 2023-12-28 | Fondazione Telethon Ets | Method for isolating hemogenic endothelial cells |
CN114958771B (zh) * | 2022-06-27 | 2023-12-05 | 广东康盾创新产业集团股份公司 | 一种ipsc-car-nk细胞的制备方法 |
WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
WO2024059070A1 (en) * | 2022-09-13 | 2024-03-21 | R.P. Scherer Technologies, Llc | Method of differentiation of pluripotent stem cells to hematopoietic precursor and stem cells |
WO2024059584A1 (en) * | 2022-09-14 | 2024-03-21 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
CN116445408B (zh) * | 2023-05-22 | 2024-02-02 | 呈诺再生医学科技(北京)有限公司 | LSD1抑制剂在促进iPSC向HSC分化和HSC干性维持中的应用 |
CN116574672B (zh) * | 2023-07-11 | 2023-10-20 | 北京北启生物医药有限公司 | 一种诱导化学诱导多能干细胞向生血内皮细胞分化的培养基及方法 |
CN117050941B (zh) * | 2023-10-11 | 2024-01-26 | 苏州艾凯利元生物科技有限公司 | 一种制备自然杀伤细胞的方法 |
CN117106714B (zh) * | 2023-10-11 | 2024-01-26 | 苏州艾凯利元生物科技有限公司 | 一种制备b细胞的方法 |
CN117050940B (zh) * | 2023-10-11 | 2024-01-26 | 苏州艾凯利元生物科技有限公司 | 一种制备自然杀伤细胞的方法 |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US5780300A (en) | 1995-09-29 | 1998-07-14 | Yale University | Manipulation of non-terminally differentiated cells using the notch pathway |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
ATE394484T1 (de) | 1997-06-13 | 2008-05-15 | Ludwig Inst Cancer Res | Smad 6 und dessen anwendungen |
WO1999001426A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
JP2004500095A (ja) | 2000-02-24 | 2004-01-08 | エクサイト セラピーズ, インコーポレイテッド | 細胞の同時の刺激および濃縮 |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
SI1301472T1 (sl) | 2000-07-19 | 2014-05-30 | Warner-Lambert Company Llc | Oksigenirani estri 4-jodo fenilamino benzihidroksamskih kislin |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
US6689744B2 (en) | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
WO2002059285A1 (en) | 2000-10-27 | 2002-08-01 | Fred Hutchinson Cancer Research Center | Methods for immortalizing cells |
US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
DK1456380T3 (da) | 2001-11-02 | 2012-07-30 | Giuliani Int Ltd | SMAD7-inhibitorer til behandling af CNS-sygdomme |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
PT2275102E (pt) | 2002-03-13 | 2015-10-27 | Array Biopharma Inc | Derivados de benzimidazole alquilado n3 como inibidores de mek |
US7575925B2 (en) | 2002-12-10 | 2009-08-18 | Sunnybrook Health Sciences Centre | Cell preparations comprising cells of the T cell lineage and methods of making and using them |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
WO2005051301A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
EP3363907A1 (en) | 2004-05-27 | 2018-08-22 | The Trustees of the University of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
US20070036769A9 (en) | 2004-06-03 | 2007-02-15 | Linheng Li | BMP pathway methods and compositions |
AR055057A1 (es) | 2005-05-18 | 2007-08-01 | Array Biopharma Inc | Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria. |
EP1992360A4 (en) | 2006-02-01 | 2010-02-17 | Univ Tokyo | USE IN ASSOCIATION OF A TGF-BETA SIGNAL INHIBITOR AND ANTITUMMER AGENT |
RU2493252C2 (ru) | 2006-03-24 | 2013-09-20 | Чилдрен'З Медикал Сентер Корпорейшн | Способ стимулирования экспансии гематопоэтических стволовых клеток |
WO2008006583A1 (en) | 2006-07-14 | 2008-01-17 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
US9175260B2 (en) | 2007-01-30 | 2015-11-03 | TheUniversity of Georgia Research Foundation, Inc. | Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (MMC) |
ES2529166T3 (es) | 2007-03-30 | 2015-02-17 | Memorial Sloan-Kettering Cancer Center | Expresión constitutiva de ligandos coestimuladores en linfocitos T transferidos de forma adoptiva |
WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
US10059923B2 (en) | 2008-01-30 | 2018-08-28 | Memorial Sloan Kettering Cancer Center | Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors |
WO2009104825A1 (en) * | 2008-02-18 | 2009-08-27 | Kaist | Method for inducing the defferentiation of embryonic stem cells into hemangioblast |
EP2789618B1 (en) | 2008-12-03 | 2016-07-27 | The Scripps Research Institute | Stem cell cultures |
WO2010087594A2 (ko) * | 2009-01-28 | 2010-08-05 | 한국생명공학연구원 | 시디93 또는 이의 가용성 단편의 용도 |
EP2398897B1 (en) | 2009-02-20 | 2017-06-28 | Cellular Dynamics International, Inc. | Methods and compositions for the differentiation of stem cells |
KR101720961B1 (ko) | 2009-02-27 | 2017-03-29 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | 다능성 세포의 분화 |
CA2756833C (en) | 2009-04-09 | 2019-11-19 | Sangamo Biosciences, Inc. | Targeted integration into stem cells |
WO2011047300A1 (en) | 2009-10-16 | 2011-04-21 | The Scripps Research Institute | Induction of pluripotent cells |
SG181601A1 (en) | 2009-12-10 | 2012-07-30 | Univ Minnesota | Tal effector-mediated dna modification |
US9206394B2 (en) | 2010-02-03 | 2015-12-08 | The University Of Tokyo | Method for reconstructing immune function using pluripotent stem cells |
JPWO2011096482A1 (ja) | 2010-02-03 | 2013-06-13 | 国立大学法人 東京大学 | 多能性幹細胞を用いた免疫機能再建法 |
US8652845B2 (en) | 2010-03-18 | 2014-02-18 | Kyoto University | Method for producing mesodermal cells by culturing under adherent conditions and without co-culture with cells from a different species in a serum-free medium |
WO2011159726A2 (en) | 2010-06-14 | 2011-12-22 | The Scripps Research Institute | Reprogramming of cells to a new fate |
JP5984217B2 (ja) | 2010-06-15 | 2016-09-06 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | 少量の末梢血からの人工多能性幹細胞の作製 |
AU2011281062B2 (en) | 2010-07-21 | 2015-01-22 | Board Of Regents, The University Of Texas System | Methods and compositions for modification of a HLA locus |
JP6043999B2 (ja) | 2010-08-05 | 2016-12-14 | ウィスコンシン アラムニ リサーチ ファンデーション | ヒト多能性細胞培養のための簡易基本培地 |
AU2011289245B2 (en) * | 2010-08-12 | 2015-01-22 | Fate Therapeutics, Inc. | Improved hematopoietic stem and progenitor cell therapy |
US9181529B2 (en) | 2010-10-19 | 2015-11-10 | Cellular Dynamics International, Inc. | Titration of differentiation medium components |
KR20140063501A (ko) | 2010-12-22 | 2014-05-27 | 페이트 세러퓨틱스, 인코포레이티드 | 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼 |
US8700106B2 (en) | 2011-03-09 | 2014-04-15 | Universal Electronics Inc. | System and method for provision of infrared signalling in smart phone devices |
CN102732483B (zh) * | 2011-03-31 | 2014-12-03 | 北京大学 | 造血祖细胞的制备方法及其专用培养基 |
US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
CA2841165A1 (en) | 2011-07-11 | 2013-01-17 | Cellular Dynamics International, Inc. | Methods for cell reprogramming and genome engineering |
EP2745840B1 (en) * | 2011-08-16 | 2017-07-12 | Samsung Life Public Welfare Foundation | Composition including stem cell-derived microvesicles for use in promoting neurogenesis |
US20130058905A1 (en) * | 2011-08-23 | 2013-03-07 | Igor Slukvin | Angiohematopoietic Progenitor Cells |
CN102329769B (zh) * | 2011-09-28 | 2013-07-31 | 浙江大学 | 一种获得造血干细胞的方法 |
WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
EP2782996B1 (en) | 2011-11-21 | 2019-03-27 | University Health Network | Populations of hematopoietic progenitors and methods of enriching stem cells therefor |
EP3785767A1 (en) | 2011-12-02 | 2021-03-03 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
WO2013086029A1 (en) | 2011-12-05 | 2013-06-13 | Primorigen Biosciences Inc. | Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof |
WO2013086436A1 (en) | 2011-12-08 | 2013-06-13 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
EP2606884A1 (en) | 2011-12-21 | 2013-06-26 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
EP3272356A1 (en) * | 2012-02-24 | 2018-01-24 | Fred Hutchinson Cancer Research Center | Compositions and methods for the treatment of hemoglobinopathies |
CA3085032A1 (en) | 2012-04-17 | 2013-10-24 | University Of Washington Through Its Center For Commercialization | Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof |
DK2839013T3 (da) | 2012-04-18 | 2020-09-14 | Univ Leland Stanford Junior | Ikke-disruptiv-gen-targetering |
WO2013163171A1 (en) | 2012-04-24 | 2013-10-31 | Kaufman Dan S | Method for developing natural killer cells from stem cells |
JP6164746B2 (ja) | 2012-05-22 | 2017-07-19 | 国立大学法人 東京大学 | 抗原特異的t細胞の製造方法 |
MA37681B2 (fr) | 2012-05-25 | 2020-07-29 | Cellectis | Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie |
WO2014011540A1 (en) | 2012-07-09 | 2014-01-16 | Emory University | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto |
KR102198058B1 (ko) | 2012-10-02 | 2021-01-06 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
SG11201503045YA (en) | 2012-10-19 | 2015-05-28 | Agency Science Tech & Res | Methods of differentiating stem cells into one or more cell lineages |
US9382531B2 (en) * | 2012-10-22 | 2016-07-05 | Wisconsin Alumni Research Foundation | Induction of hemogenic endothelium from pluripotent stem cells |
US9255250B2 (en) | 2012-12-05 | 2016-02-09 | Sangamo Bioscience, Inc. | Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene |
CA2896053A1 (en) | 2012-12-21 | 2014-06-26 | Ocata Therapeutics, Inc. | Methods for production of platelets from pluripotent stem cells and compositions thereof |
CA3141731A1 (en) * | 2013-03-13 | 2014-10-09 | Wisconsin Alumni Research Foundation | Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions |
AU2014386824B2 (en) | 2013-03-15 | 2019-05-09 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
EP3789487A1 (en) | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
EP4286517A3 (en) * | 2013-04-04 | 2024-03-13 | President and Fellows of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
US9381210B2 (en) * | 2013-04-15 | 2016-07-05 | Wisconsin Alumni Research Foundation | Induced pluripotent stem cell model of chronic myeloid leukemia revealed olfactomedin 4 as a novel therapeutic target in leukemia stem cells |
JP6493881B2 (ja) * | 2013-06-12 | 2019-04-03 | 国立大学法人京都大学 | 人工多能性幹細胞の選別方法および血球への分化誘導方法 |
CN103361310B (zh) * | 2013-06-25 | 2015-09-23 | 中国人民解放军军事医学科学院野战输血研究所 | 培养基、试剂盒及其用途 |
WO2015057976A1 (en) | 2013-10-17 | 2015-04-23 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
US9932607B2 (en) | 2013-11-15 | 2018-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Site-specific integration of transgenes into human cells |
EP3604499A1 (en) | 2014-03-04 | 2020-02-05 | Fate Therapeutics, Inc. | Improved reprogramming methods and cell culture platforms |
EP3122769B1 (en) | 2014-03-28 | 2023-02-22 | Regents of the University of Minnesota | Polypeptides, cells, and methods involving engineered cd16 |
CN103937743B (zh) * | 2014-04-27 | 2017-12-01 | 浙江大学 | 一种利用三维诱导***获得造血干细胞的方法 |
JP2018504122A (ja) | 2015-01-26 | 2018-02-15 | フェイト セラピューティクス,インコーポレイテッド | 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 |
US10626372B1 (en) | 2015-01-26 | 2020-04-21 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
CN104745529B (zh) * | 2015-03-13 | 2019-03-05 | 华南生物医药研究院 | 瘦素在诱导胚胎干细胞分化为造血干/祖细胞中的用途及其应用 |
US20170020922A1 (en) * | 2015-07-16 | 2017-01-26 | Batu Biologics Inc. | Gene editing for immunological destruction of neoplasia |
EP4108255A1 (en) | 2015-10-05 | 2022-12-28 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
CN108368520B (zh) | 2015-11-04 | 2023-01-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
CA3003152A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
JP7000311B2 (ja) | 2016-03-23 | 2022-02-04 | 国立大学法人京都大学 | 血球分化能の高い中胚葉誘導方法 |
EP4180519A1 (en) | 2016-04-15 | 2023-05-17 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
-
2016
- 2016-07-26 CA CA3003152A patent/CA3003152A1/en active Pending
- 2016-07-26 SG SG11201803145RA patent/SG11201803145RA/en unknown
- 2016-07-26 KR KR1020187015759A patent/KR20180066263A/ko not_active Application Discontinuation
- 2016-07-26 JP JP2018521543A patent/JP2018533363A/ja active Pending
- 2016-07-26 CN CN202211397675.5A patent/CN115927199A/zh active Pending
- 2016-07-26 EP EP16862624.0A patent/EP3371301A4/en active Pending
- 2016-07-26 WO PCT/US2016/044122 patent/WO2017078807A1/en active Application Filing
- 2016-07-26 AU AU2016348342A patent/AU2016348342B2/en active Active
- 2016-07-26 CN CN201680073326.4A patent/CN108473961B/zh active Active
- 2016-07-26 US US15/773,519 patent/US10858628B2/en active Active
-
2020
- 2020-10-02 US US17/062,475 patent/US11162075B2/en active Active
- 2020-10-02 US US17/062,478 patent/US10947505B2/en active Active
-
2021
- 2021-03-11 US US17/199,301 patent/US11162076B2/en active Active
- 2021-03-12 US US17/200,351 patent/US20210230549A1/en active Pending
-
2022
- 2022-01-04 JP JP2022000188A patent/JP2022058480A/ja active Pending
-
2023
- 2023-06-20 AU AU2023203874A patent/AU2023203874A1/en active Pending
-
2024
- 2024-02-02 JP JP2024015135A patent/JP2024054194A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2017078807A9 (en) | 2018-08-09 |
CN108473961B (zh) | 2022-11-29 |
US11162076B2 (en) | 2021-11-02 |
KR20180066263A (ko) | 2018-06-18 |
WO2017078807A1 (en) | 2017-05-11 |
EP3371301A1 (en) | 2018-09-12 |
US20210230549A1 (en) | 2021-07-29 |
US20210024891A1 (en) | 2021-01-28 |
US20210222126A1 (en) | 2021-07-22 |
US10858628B2 (en) | 2020-12-08 |
AU2023203874A1 (en) | 2023-07-13 |
EP3371301A4 (en) | 2019-06-26 |
CN108473961A (zh) | 2018-08-31 |
AU2016348342B2 (en) | 2023-07-06 |
CN115927199A (zh) | 2023-04-07 |
JP2022058480A (ja) | 2022-04-12 |
CA3003152A1 (en) | 2017-05-11 |
US20210062151A1 (en) | 2021-03-04 |
US20180320137A1 (en) | 2018-11-08 |
US10947505B2 (en) | 2021-03-16 |
AU2016348342A1 (en) | 2018-05-10 |
JP2018533363A (ja) | 2018-11-15 |
US11162075B2 (en) | 2021-11-02 |
JP2024054194A (ja) | 2024-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1247245A1 (zh) | 用於誘導造血細胞分化的方法和組合物 | |
SG11201803145RA (en) | Methods and compositions for inducing hematopoietic cell differentiation | |
HK1243333A1 (zh) | 用於修飾的t細胞的方法和組合物 | |
HK1257295A1 (zh) | 用於免疫腫瘤學的組合物和方法 | |
HK1244841A1 (zh) | 用於選擇性消除所關注細胞的方法和組合物 | |
HK1259151A1 (zh) | 用於在造血幹細胞中基因編輯的方法和組合物 | |
HK1244826A1 (zh) | 用於過繼細胞治療的方法和組合物 | |
IL259321A (en) | Preparations and methods for increasing gene expression in frogs | |
HK1245080A1 (zh) | 自然殺傷細胞的方法和組合物 | |
KR102377396B1 (ko) | Th17 세포의 유도를 위한 조성물 및 방법 | |
ZA201900225B (en) | Methods and compositions for gene expression in plants | |
HK1255101A1 (zh) | 用於得到調節性t細胞的方法及其用途 | |
IL246879B (en) | Preparations of Epilimod and methods of using them | |
HK1245158A1 (zh) | 阿吡莫德組合物及其使用方法 | |
EP3307284A4 (en) | COMPOSITIONS AND METHOD FOR ENRICHMENT OF CELLS | |
HK1246193A1 (zh) | 用於改善認知的方法和組合物 | |
HUE054259T2 (hu) | Sejttenyészet | |
HK1257421A1 (zh) | Bag3 組合物和方法 | |
KR101819190B9 (ko) | 미세조류 파괴용 조성물 | |
GB201401373D0 (en) | Compositions for cells lysis and uses thereof | |
SG11201801873TA (en) | Process and compositions for achieving mammalian energy balance | |
EP3230440A4 (en) | Compositions and methods for neuronal differentiation of cells | |
AU2014904953A0 (en) | Compositions and methods for neuronal differentiation of cells |